Kancera reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study and that Dr. Hanjing Xie has been appointed to Chief Medical Officer
Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology
Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
Kancera reports new preclinical results supporting potential for its ROR1 inhibitor in B-cell malignancies
Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma
Kancera reports good progress of recruitment in ongoing phase IIa study of KAND567 in myocardial infarction and the decision to allow for recruitment of additional patients
Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer
